Utility of ProGRP Determinations in Cancer Patients
Wojcik, E.; Rychlik, U.; Skotnicki, P.; Jakubowicz, J.; Kulpa, J.K.
Clinical Laboratory 56(11-12): 527-534
2010
ISSN/ISBN: 1433-6510 PMID: 21141436 Document Number: 15974
Background: The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy. Materials and methods: The study involved a reference group and a population of lung, breast, ovarian, and prostate cancer patients. ProGRP was evaluated using two-step chemiluminescent microparticle immunoassay (CMIA) manufactured by Abbott Diagnostics, and Architect i2000 analyzer. Results: During follow-up of SCLC patients, an increased value for ProGRP was found in 51 % and for NSE only in 25.5 % of the patients, whereas in NSCLC patients, percentages with elevated ProGRP and CYFRA 21-1 were 8.6 % and 55.7 %, respectively. SCLC patients also had the highest AUC values for ProGRP. In other cancers, the frequency of elevated ProGRP results were as follows: 13.1 % - in breast cancer patients, 19.6 % - in ovarian cancer patients, and 15.1 % - in prostate cancer patients. Conclusions: The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies.
Document emailed within 1 workday
